Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is a biotechnology company engaged in the development of advanced preclinical platforms and predictive tumor specific data to improve the value of oncology drugs. The Company's Preclinical Platform is based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The Company is building its Biomerk Tumorgraft platform through the procurement, development and characterization of numerous Tumorgrafts within each of several cancer types. Tumorgrafts are procured through agreements with institutions in the United States and Europe and developed and tested through agreement with a United States-based preclinical facility.
View in Other Languages
News
After hearing the words, "you've got cancer," most patients are given a drug or combination of agents according to guidelines or standards of care. These treatments, in the oncologist's best judgment, are considered most likely to work based on the results of clinical studies in patients with similar tumor types. Cancer patients often require several courses of drugs and regimens sequentially, that are ineffective or poorly tolerated, prior to identifying the optimal therapy.
###
4,223 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 5) (Last 30 Days: 24) (Since Published: 1899)
